Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Acumen Pharmaceuticals (NASDAQ: ABOS) will report fourth quarter and year-end 2025 financial results on March 26, 2026 and will host a conference call and live audio webcast at 8:00 a.m. ET.
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) will report fourth quarter and year-end 2025 financial results on March 26, 2026 and will host a conference call and live audio webcast at 8:00 a.m. ET.
According to the company, registration is required for dial-in details, the live webcast link is provided, and an archived webcast will be available for at least 30 days in Investors on www.acumenpharm.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ABOS
In the Mar 20 session, ABOS declined 8.56%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings release date
- March 26, 2026
- Scheduled Q4 and year-end 2025 results
- Conference call time
- 8:00 a.m. ET
- Earnings and business update webcast
- Webcast archive period
- 30 days
- Replay availability in Investors section of website
Historical Context
-
New AD/PD 2026 preclinical and biomarker data on brain delivery and antibodies.
-
$35.75M private placement at $3.30 per share to fund EBD program.
-
Announcement of fireside chat at Stifel 2026 Virtual CNS Forum.
-
Plan to present EBD, biomarkers, and AβO antibodies at AD/PD 2026.
-
CTAD data on enhanced brain delivery and ALTITUDE‑AD recruitment metrics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
ICR Healthcare
AcumenPR@icrhealthcare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.